ANL
Adlai Nortye Ltd.
NASDAQ · Healthcare · Biotechnology · KY
$15.74
+3.01%Next report
Analyst consensus
- Next report date
- Mar 3, 2027
- EPS estimate
- -$0.15
- Revenue estimate
- $3.5M
Latest reported
- Last report date
- Aug 14, 2026
- EPS actual
- -$0.04
- EPS estimate
- -$0.04
- Revenue actual
- $14.7M
- Revenue estimate
- $12.5M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 1
- EPS in line (12Q)
- 3
- Avg surprise (4Q)
- +2.0%
- Revenue beats (12Q)
- 1
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $26
- PT range
- $20 – $31
- Analysts
- 3
3 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 14, 2026 | -$0.04 | -$0.04 | Beat 7.92% | $14.7M |
| Apr 10, 2026 | -$0.10 | -$0.10 | In line | $10.0M |
| Dec 29, 2025 | -$0.18 | -$0.18 | In line | — |
| Aug 7, 2025 | -$0.18 | -$0.18 | In line | — |
| Apr 30, 2025 | -$0.53 | -$0.22 | Beat 58.49% | — |
| Feb 26, 2025 | -$0.53 | -$0.22 | Beat 58.49% | — |
| Aug 8, 2024 | -$1.06 | -$0.53 | Beat 50.15% | $745.0K |
| Apr 20, 2024 | -$0.38 | -$0.65 | Miss -70.52% | $2.5M |
| Mar 30, 2024 | — | -$0.53 | — | $745.0K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Mar 3, 2027